Cerespir Incorporated Appoints Sophie Egholm As The New Chief Operating Officer

Cerespir Incorporated Appoints Sophie Egholm As The New Chief Operating Officer
CereSpir™ Incorporated, a biotechnology company firm advancing CSP-1103, which is a first-in-class modulator of the innate immune system of the brain to address treatment for Alzheimer's disease, recently announced that Sophie Egholm has been appointed as Chief Operating Officer of the company. Egholm is a pharmacologist and medicinal chemist who has spent her whole career in the pharmaceutical industry as a holder of senior management positions, thanks to her excellent track record in Finance, Business and Operations Management with top experience in clinical trials specifically designed for Alzheimer's. CereSpir™ is advancing CSP-1103, an orally delivered tablet with high potential to treat Mild Cognitive Impairment (MCI) thanks to targeting the stage of symptomatic disease before the onset of dementia. CSP-1103 is now under Phase 2 testing in individuals with MCI and CereSpir's phase 3 program is being finalized based on input from the United States Food Drug Administration, European Medicines Agency and Japanese Pharmaceuticals and Medical Device Agency (PMDA). The firm is also planning an orphan drug development program to be developed in parallel for Batten disease. Egholm's career includes being the both the Head of Operations and President of the Clinical Trials Business Unit at Cogstate Ltd, Associate Director, Strategic Alliances and Worldwide Business Development at Pfizer. She was also the Global Marketing Manager at UCB BIOPRODUCTS in Belgium. Egholm received her Master's degree in Engineerin
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *